PharmaEngine, Inc.

Taipei Exchange 4162.TWO

PharmaEngine, Inc. EBITDA for the year ending December 31, 2023: USD 11.31 M

PharmaEngine, Inc. EBITDA is USD 11.31 M for the year ending December 31, 2023, a -13.55% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

PharmaEngine, Inc. EBITDA for the year ending December 31, 2022 was USD 13.09 M, a -34.74% change year over year.
PharmaEngine, Inc. EBITDA for the year ending December 31, 2021 was USD 20.05 M, a -26.32% change year over year.
PharmaEngine, Inc. EBITDA for the year ending December 31, 2020 was USD 27.21 M, a 1,341.18% change year over year.
PharmaEngine, Inc. EBITDA for the year ending December 31, 2019 was USD 1.89 M, a -65.36% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Taipei Exchange: 4162.TWO

PharmaEngine, Inc.

CEO	Mr. Hong-Ren Wang Ph.D.
IPO Date	June 20, 2012
Location	Taiwan
Headquarters	10 Minsheng East Road
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

Key trends

Past 5 years